Previous 10 | Next 10 |
2024-05-02 10:25:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During the first quarter, Baron Opportunity Fund rose 15.33%, outperforming the broade...
2024-04-28 10:30:00 ET Viking Therapeutics (NASDAQ: VKTX) has emerged as a beacon of hope in an otherwise lackluster year for healthcare stocks. The buzz around its mid-stage weight loss candidate, VK2735, has propelled the biotech's stock to a staggering 714% surge since the comple...
2024-04-28 09:07:00 ET Viking Therapeutics (NASDAQ: VKTX) has been flying on all cylinders since the beginning of the year. The company's shares are up 246% due to excellent clinical progress. It's not rare for smaller biotechs to see their stock prices skyrocket relatively quickly,...
2024-04-28 05:44:58 ET Summary Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively. Mid-single digit sales growth is expected to remain with the pipeline that it has established thus f...
2024-04-26 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you follow Warren Buffett’s advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis ce...
2024-04-24 19:58:10 ET Viking Therapeutics, Inc. (VKTX) Q1 2024 EarninConference Call April 24, 2024 08:30 A.M. ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Of...
2024-04-24 18:25:10 ET More on Viking Therapeutics Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead Viking Therapeutics: Future Weight Loss Heavyweight? Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeu...
2024-04-24 16:14:16 ET More on Viking Therapeutics Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead Viking Therapeutics: Future Weight Loss Heavyweight? Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeu...
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-...
2024-04-24 13:02:30 ET Summary Madrigal Pharmaceuticals, Inc. recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035, making it a significant opportunity for Madrigal Phar...
News, Short Squeeze, Breakout and More Instantly...
Viking Therapeutics Inc. Company Name:
VKTX Stock Symbol:
NASDAQ Market:
Viking Therapeutics Inc. Website:
2024-07-20 06:00:00 ET California's giant redwood trees were once tiny sprouts or seeds. Likewise, the world's biggest companies were once much smaller. Trees and companies can grow significantly over time -- at least some of them. Three Motley Fool contributors think they've found bi...
2024-07-19 05:50:00 ET Fortunes have been made on biotech stocks over the last few decades. The secret to success has been to invest in an up-and-coming biotech company before it even had a product on the market. Ideally, the company would have a pipeline featuring multiple promising candid...
Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 PR Newswire Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO , July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc...